Medicure Inc has seen notable movements in its stock price recently, with a mix of gains and losses amidst significant news.
This week, Medicure Inc (MPH.V) experienced a slight decline of 3.86% in its stock price, closing at C$2.50. However, the stock has shown strong performance over the past month with a 94.53% increase, and an impressive year-to-date rise of 118.42%. Let's delve into the recent developments that may be influencing investor sentiment.
Investor takeaway: Despite the recent dip, Medicure's strong performance over the past month and year indicates growing investor interest, particularly following important news regarding its ongoing clinical trials.
Advertisement
Medicure Inc
MPH.V
MPH.V
Medicure Inc
WealthAwesomeMarket cap
$31.10M
52W high
$4.95
52W low
$0.85
1W change
+26.28%
Beta
1.15
Analyst Price Targets
Based on analyst covering MPH · as of Sep 17, 2026
Wall Street analysts forecast MPH stock price to fall 24.3% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.80
-24.3% Upside
Current Price
C$3.70
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MPH's historical volatility
30-Day Vol
125.8%
Annualized
90-Day Vol
135.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$4.42
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.93 | C$2.54 – C$6.06 |
| 60 trading days | C$4.17 | C$2.26 – C$7.70 |
| 90 trading days | C$4.42 | C$2.09 – C$9.38 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Medicure Inc's stock has surged 94.53% over the past month.
With a market cap of approximately C$26.1 million and a significant increase in stock value, the company's growth trajectory is noteworthy, yet it faces challenges with profitability.
Bull case
Medicure's stock performance has been boosted by its promising pipeline, especially the MEND-PNPO Phase 3 study, which was recently presented at a major epilepsy congress. This progress in clinical trials is encouraging for investors looking for potential breakthroughs in treatment options.
Bear case
On the other hand, the company's negative profit margin and return on equity raise concerns about its financial health. These factors could impact long-term investor confidence, even with the recent gains in stock value.
Recent Price Action
Advertisement
In the latest trading session, Medicure Inc's stock closed at C$2.50, reflecting a decrease of 3.86%. Despite this dip, the stock has shown resilience with a 1.63% increase over the past week. The year-to-date performance is particularly notable, with a remarkable gain of 118.42%. Investors are closely monitoring these fluctuations as the company continues to develop its product pipeline.
Company News and Catalysts
On September 8, 2026, Medicure presented its MEND-PNPO Phase 3 study design and baseline data at the 16th European Epilepsy Congress. This presentation is a significant catalyst for the company, as it highlights the progress of its clinical programs and may influence investor sentiment positively. The focus on epilepsy treatment is timely, given the increasing demand for innovative therapies in the healthcare sector.
Technical Picture
From a technical perspective, Medicure's stock is trading well above both its 50-day moving average of C$1.47 and its 200-day moving average of C$1.23, indicating strong upward momentum. The stock's 52-week range is C$0.85 to C$2.74, with the current price sitting at approximately 87% of this range. With a beta of 1.27, the stock exhibits higher volatility compared to the market, making it a stock that may appeal to risk-tolerant investors.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
